NCT05109728 2026-03-16
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.
Novartis
Phase 1 Active not recruiting
Novartis
Janssen Pharmaceutica N.V., Belgium
Merck Sharp & Dohme LLC
Inovio Pharmaceuticals
Hoffmann-La Roche
Graegis Pharmaceuticals Ltd
Merck Sharp & Dohme LLC
DEKA Biosciences
Merck Sharp & Dohme LLC